EVerZom and GENFIT team up on exosome therapy for severe liver disease

French biotech EVerZom has signed its first research partnership with compatriot GENFIT to evaluate EViv, an exosome-based drug candidate for acute-on-chronic liver failure (ACLF), a life-threatening condition with few treatment options beyond transplantation. GENFIT will oversee preclinical testing, with an 18-month decision window on clinical development rights.

EVerZom will contribute its proprietary exosome know-how and bioproduction platform, while GENFIT applies its expertise in rare liver disorders. If results are positive, GENFIT may exercise an exclusive license covering acute liver diseases. The companies said the alliance marks a major step toward demonstrating the broader potential of exosomes in regenerative medicine.

EViv is designed as an intravenous therapy that dampens inflammatory cytokines while stimulating anti-inflammatory and tissue-repair pathways. According to chief executive Jeanne Volatron, the project fits the company’s strategy to show “the clinical versatility of exosomes” across regenerative fields such as hepatology, dermatology, and ophthalmology.